Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mesoblast ( (MESO) ) has provided an announcement.
On November 25, 2025, Mesoblast Limited announced the results of its Annual General Meeting, where all proposed resolutions were passed by a poll. The resolutions included the adoption of the remuneration report, election and re-election of directors, approval of options for long-term and short-term incentives, and the approval of convertible notes and warrants. These outcomes reflect strong shareholder support and are likely to positively impact the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score is driven by financial challenges and bearish technical indicators. Despite strong revenue growth and positive earnings call highlights, the company’s profitability issues and negative valuation metrics weigh heavily on the score. The potential for future growth, as indicated in the earnings call, provides some optimism.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is a company based in Australia, primarily involved in the development of innovative cellular medicines. The company focuses on regenerative medicine and cell therapy products, targeting conditions such as cardiovascular diseases, inflammatory ailments, and immune-mediated diseases.
Average Trading Volume: 240,229
Technical Sentiment Signal: Buy
Current Market Cap: $1.93B
See more data about MESO stock on TipRanks’ Stock Analysis page.